Potential expansion Telomere Diagnostics operates as a high-throughput CLIA-certified clinical lab currently focused on COVID-19 testing with national scale and comprehensive clinical and digital solutions. A clear sales opportunity lies in expanding beyond COVID-19 testing into broader infectious disease panels or genetic/biomarker testing leveraging existing lab capabilities and digital reporting infrastructure.

Diagnostics partnerships With a robust digital solutions stack and a national testing footprint, there is potential to partner with large healthcare systems, ambulatory networks, or employer health programs to offer streamlined testing, result reporting, and data integration via common platforms used in BD processes.

Strategic customers Given the small company size and CLIA-certified lab capabilities, target mid to large employers, biotech sponsors, and reference labs that require scalable, compliant testing services, broadening revenue through contract-based testing, surveillance programs, or white-label diagnostic services.

Technology leverage Existing tech stack including analytics, user behavior tools, and payment processing suggests opportunities to upsell data-driven health insights, automated reporting, and seamless payer workflows, as well as pilot programs for other diagnostic assays using the current cloud and analytics infrastructure.

Market positioning Teloyears has a notable branding angle with Nobel prize association and telomere testing heritage. This can be leveraged to differentiate offerings in oncology wellness, aging biology, and personalized medicine testing segments, aligning sales pitches to precision health and preventive care markets.